11 results on '"Paris, Laura"'
Search Results
2. Evaluating barriers to reaching women with public health information in remote communities in Mali.
- Author
-
Jones, Robert T., Spencer, Freya I., Paris, Laura A., Soumaïla, Diarra, Kamara, Nanthilde, Hiscox, Alexandra, and Logan, James G.
- Subjects
- *
COMMUNITY health workers , *COMMUNITY centers , *MOBILE operating systems , *MEDICAL centers , *TRUST - Abstract
Telecommunications offers an alternative or supplement to community-based interventions as a means of extending healthcare services and improving health outcomes in remote settings but can fail to reach target communities and achieve the desired impact if barriers to access are not overcome. We conducted seven focus group discussions and 26 interviews with community health workers, community leaders, and female members of the public who declared that they had or had not previously accessed free audio health messages provided via a mobile platform in two rural communities of Mali, Koulikoro and Bougouni. A content analysis showed that participants accessed and trusted health information from a range of sources, including radio, telephone and television, as well as town criers, local relays and community health centres. Barriers to access faced by women included economic factors, lack of network or electricity, and social factors such as illiteracy, cultural restrictions and being unaware of mobile communication. Through analysis and interpretation of the participants' responses, we have made recommendations for future campaigns for the dissemination of health-related information for women in remote settings. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Anticoagulation and Antiplatelet Regimen in Cardiac Transplant. Clinical Characteristics, Outcomes, and Blood Product Transfusion.
- Author
-
Groba Marco, Maria del Val, Saavedra Santana, Pedro, Gonzalez del Castillo, Luz Maria, Galvan Ruiz, Mario, de Fernandez de Sanmamed, Miguel, Urso, Stefano, Guerra Hernández, Elisabet, Quintana Paris, Laura, Tout Castellano, Michelle, Romero Lujan, Jose Luis, Caballero Dorta, Eduardo Jose, Guerra Dominguez, Luisa Maria, and Garcia Quintana, Antonio
- Subjects
- *
HEART transplantation , *BLOOD transfusion , *BLOOD platelet transfusion , *BLOOD products , *ANTICOAGULANTS , *ERYTHROCYTES - Abstract
Background: We aimed to evaluate the characteristics, clinical outcomes, and blood product transfusion (BPT) rates of patients undergoing cardiac transplant (CT) while receiving uninterrupted anticoagulation and antiplatelet therapy. Methods: A retrospective, single‐center, and observational study of adult patients who underwent CT was performed. Patients were classified into four groups: (1) patients without anticoagulation or antiplatelet therapy (control), (2) patients on antiplatelet therapy (AP), (3) patients on vitamin K antagonists (AVKs), and (4) patients on dabigatran (dabigatran). The primary endpoints were reoperation due to bleeding and perioperative BPT rates (packed red blood cells (PRBC), fresh frozen plasma, platelets). Secondary outcomes assessed included morbidity and mortality‐related events. Results: Of the 55 patients included, 6 (11%) received no therapy (control), 8 (15%) received antiplatelet therapy, 15 (27%) were on AVKs, and 26 (47%) were on dabigatran. There were no significant differences in the need for reoperation or other secondary morbidity‐associated events. During surgery patients on dabigatran showed lower transfusion rates of PRBC (control 100%, AP 100%, AVKs 73%, dabigatran 50%, p = 0.011) and platelets (control 100%, AP 100%, AVKs 100%, dabigatran 69%, p = 0.019). The total intraoperative number of BPT was also the lowest in the dabigatran group (control 5.5 units, AP 5 units, AVKs 6 units, dabigatran 3 units; p = 0.038); receiving significantly less PRBC (control 2.5 units, AP 3 units, AVKs 2 units, dabigatran 0.5 units; p = 0.011). A Poisson multivariate analysis showed that only treatment on dabigatran reduces PRBC requirements during surgery, with an expected reduction of 64.5% (95% CI: 32.4%–81.4%). Conclusions: In patients listed for CT requiring anticoagulation due to nonvalvular atrial fibrillation, the use of dabigatran and its reversal with idarucizumab significantly reduces intraoperative BPT demand. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Humanistic burden of haemophilia A without inhibitors: A cross‐sectional analysis of the HemoLIFE study.
- Author
-
Álvarez‐Román, María Teresa, Nuñez Vazquez, Ramiro Jose, Benitez Hidalgo, Olga, Quintana Paris, Laura, Entrena Ureña, Laura, Lopez Jaime, Francisco Jose, la De Corte‐Rodríguez, Hortensia, García Dasí, María, Bosch, Pau, Mingot Castellano, María Eva, Guerra Garaeta, Itziar, and Soto‐Ortega, Inmaculada
- Subjects
- *
HEMOPHILIA , *CROSS-sectional method , *HEMOPHILIACS , *CHILD patients , *LABOR productivity - Abstract
Aim: To evaluate the impact of haemophilia A without inhibitors on humanistic outcomes in patients and caregivers. Herein, we report a cross‐sectional analysis of the baseline data of persons with haemophilia (PWH) participating in the prospective study HEMOLIFE. Methods: These data are part of a prospective, observational, and multicentre study currently being conducted in 20 hospitals in Spain by haematologists. We included subjects 12 years or older diagnosed with haemophilia. The evaluations included the Maladjustment Scale, Haemophilia–Specific Quality of Life Questionnaire for Adults (HaemoQol)/HaemoQol Short Form (Children), haemophilia‐specific version of the Work Productivity and Impairment Questionnaire plus the Classroom Impairment Questionnaire (WPAI+CIQ:HS), Haemophilia Activity List (HAL)/Paediatric Haemophilia Activities List (pedHAL), visual analogue scale (VAS) for evaluating pain, Coping Pain Questionnaire–Reduced (CAD‐R), and Hospital Anxiety and Depression Scale (HADS). Results: A total of 81 PWH were recruited at 18 centres; 66 PWH were ≥18 years (i.e., adults), and PWH 15 were <18 years (i.e., paediatric patients). Out of the 79 evaluable subjects, 16 (20%) showed an impact of haemophilia on daily life, and the areas most affected were "leisure time" (58% showed maladjustment) and "work/studies" (47% showed maladjustment). Patients reported a higher impact of haemophilia on quality of life (mean [SD] of the transformed score) in the dimensions of "sport" (49.4 [28.6]), "physical health" (40.5 [25.8]) and "future" (37.7 [28.9]). In adults, according to HAL scores, greater impairment of function was observed in "lying/sitting/kneeling/standing," "function of legs" and "leisure activities and sports," with mean normalized scores of 64.7, 65.1 and 69.0, respectively. Productivity was mostly impacted by presenteeism. The pain was infrequent and moderate. According to the HADS scores, nine (11.5%) patients had clinical anxiety and depression. Conclusion: PWH without inhibitors exhibited impairments in adjustment, quality of life and functionality, especially related to leisure and sports activities, and exhibit relevant levels of anxiety and depression. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. VALIDACIÓN DEL INVENTARIO DE BIENESTAR SUBJETIVO CON MUESTRAS DE JÓVENES Y ADOLESCENTS ARGENTINOS, BRASILEROS Y MEXICANOS.
- Author
-
Omar, Alicia, Paris, Laura, de Souza, Marcos Aguiar, da Silva, Sérgio Henrique Almeida, and Peña, Rebeca del Pino
- Subjects
- *
PSYCHOLOGICAL well-being , *ADOLESCENT psychology , *PSYCHOLOGICAL resilience , *STRESS management , *WIT & humor , *ARGENTINE wit & humor - Abstract
The aim of this study was to adapt the Well-Being Inventory of Nacpal & Shell for using with Latinamerican youth and adolescents. The conceptual, semantic and operational equivalence of inventory prototype version was analized. The final version was administered to a sample of 1,891 students (730 Mexicans, 664 Argentines and 497 Brazilians) who also filled a set of recognized instruments developed to explore resilience, coping, sense of humor, emotional intelligence and cultural values. The exploration of factorial validity showed six orthogonal factors which explained almost 59% of total variance. Construct validity was demostrated through positive and significant correlations between subjective well-being and most of the variables considered. Reliability of the adapted instrument reached satisfactory levels. In light of the results some suggestions for future research in the area are made. [ABSTRACT FROM AUTHOR]
- Published
- 2009
6. A Rare Case of Atypical Palatal‐Lingual Tremor Associated with Waldenström's Macroglobulinemia.
- Author
-
Storti, Benedetta, Gallone, Annamaria, Paris, Laura, and Foresti, Camillo
- Subjects
- *
TREMOR , *ESSENTIAL tremor , *CEREBROSPINAL fluid examination , *DRUG abuse , *BLINKING (Physiology) - Abstract
A Rare Case of Atypical Palatal-Lingual Tremor Associated with Waldenström's Macroglobulinemia GLO:JZVX/01jul21:mdc313217-fig-0001.jpg PHOTO (COLOR): 1 The needle examination of tensor veli palatini showed a rhythmic 4 Hz spontaneous activity synchronous with the palatal tremor. gl The patient was admitted to the hospital for further evaluation and treatment. A 71-year-old man presented at the general neurologic clinic with palatal-lingual tremor started one year earlier (Video 1). [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
7. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
- Author
-
Mina, Roberto, Musto, Pellegrino, Rota-Scalabrini, Delia, Paris, Laura, Gamberi, Barbara, Palmas, Angelo, Aquino, Sara, de Fabritiis, Paolo, Giuliani, Nicola, De Rosa, Luca, Gozzetti, Alessandro, Cellini, Claudia, Bertamini, Luca, Capra, Andrea, Oddolo, Daniela, Vincelli, Iolanda Donatella, Ronconi, Sonia, Pavone, Vincenzo, Pescosta, Norbert, and Cea, Michele
- Subjects
- *
STEM cell transplantation , *AUTOTRANSPLANTATION , *MULTIPLE myeloma , *KARNOFSKY Performance Status , *MONOCLONAL gammopathies , *SUBGROUP analysis (Experimental design) - Abstract
Patients with newly diagnosed multiple myeloma and high-risk cytogenetic abnormalities (HRCA) represent an unmet medical need. In the FORTE trial, lenalidomide and dexamethasone plus carfilzomib (KRd) induction resulted in a higher proportion of patients with at least a very good partial response as compared with carfilzomib, cyclophosphamide, and dexamethasone (KCd), and carfilzomib plus lenalidomide maintenance prolonged progression-free survival compared with lenalidomide maintenance. In this prespecified analysis of the FORTE trial, we described the outcomes of enrolled patients according to their cytogenetic risk. The UNITO-MM-01/FORTE was a randomised, open-label, phase 2 trial done at 42 Italian academic and community practice centres, which enrolled transplant-eligible patients with newly diagnosed multiple myeloma aged 18–65 years. Eligible patients had newly diagnosed multiple myeloma based on standard International Myeloma Working Group criteria, a Karnofsky performance status of at least 60%, and had not received any previous treatment with anti-myeloma therapy. At enrolment, patients were stratified according to International Staging System stage (I vs II/III) and age (<60 years vs 60–65 years) and randomly assigned (1:1:1) to KRd plus autologous stem-cell transplantation (ASCT; four 28-day induction cycles with KRd, melphalan at 200 mg/m2 and ASCT [MEL200-ASCT], followed by four 28-day KRd consolidation cycles), 12 28-day KRd cycles, or KCd plus ASCT (four 28-day induction cycles with KCd, MEL200-ASCT, and four 28-day KCd consolidation cycles), using a web-based system (block randomisation, block size of 12). Carfilzomib was administered at 20 mg/m2 on days 1 and 2 of cycle 1, followed by 36 mg/m2 intravenously administered on days 8, 9, 15, and 16 of cycle 1, and then 36 mg/m2 intravenously administered for all subsequent doses on days 1, 2, 8, 9, 15, 16; lenalidomide 25 mg was administered orally on days 1–21; cyclophosphamide 300 mg/m2 was administered orally on days 1, 8, and 15; and dexamethasone 20 mg was administered orally or intravenously on days 1, 2, 8, 9, 15, 16, 22, and 23. After the consolidation phase, patients were stratified according to induction–consolidation treatment and randomly assigned (1:1; block size of 8) to maintenance treatment with carfilzomib plus lenalidomide or lenalidomide alone. Carfilzomib 36 mg/m2 was administered intravenously on days 1–2 and days 15–16, every 28 days for up to 2 years, and lenalidomide 10 mg was administered orally on days 1–21 every 28 days until progression or intolerance in both groups. The primary endpoints were the proportion of patients with at least a very good partial response after induction with KRd versus KCd and progression-free survival with carfilzomib plus lenalidomide versus lenalidomide alone as maintenance treatment. In this preplanned analysis, we included patients enrolled in the FORTE trial with complete cytogenetic data on del(17p), t(4;14), t(14;16), del(1p), gain(1q) (3 copies), and amp(1q) (≥4 copies) assessed by fluorescence in-situ hybridisation analysis on CD138-positive sorted cells. We assessed progression-free survival, overall survival, minimal residual disease negativity, and 1-year sustained minimal residual disease negativity according to the presence of zero, one, and two or more HRCA across treatment groups. The FORTE trial is ongoing, and registered with ClinicalTrials.gov , NCT02203643. Between Feb 23, 2015, and April 5, 2017, 477 patients were enrolled, of whom 396 (83%) had complete cytogenetic data and were analysed (176 [44%] of whom were women and 220 [56%] were men). The median follow-up from first randomisation was 51 months (IQR 46–56). 4-year progression-free survival was 71% (95% CI 64–78) in patients with zero HRCA, 60% (95% CI 52–69) in patients with one HRCA, and 39% (95% CI 30–50) in patients with two or more HRCA. Compared with patients with zero HRCA, the risk of progression or death was similar in patients with one HRCA (hazard ratio [HR] 1·33 [95% CI 0·90–1·97]; p=0·15) and higher in patients with two or more HRCA (HR 2·56 [95% CI 1·74–3·75]); p<0·0001) across the induction–intensification–consolidation groups. Moreover, the risk of progression or death was also higher in patients with two or more HRCA versus those with one HRCA (HR 1·92 [95% CI 1·34–2·76]; p=0·0004). 4-year overall survival from the first randomisation was 94% (95% CI 91–98) in patients with zero HRCA, 83% (95% CI 76–90) in patients with one HRCA, and 63% (95% CI 54–74) in patients with two or more HRCA. Compared with patients with zero HRCA, the risk of death was significantly higher in patients with one HRCA (HR 2·55 [95% CI 1·22–5·36]; p=0·013) and two or more HRCA (HR 6·53 [95% CI 3·24–13·18]; p<0·0001). Patients with two or more HRCA also had a significantly higher risk of death than those with one HRCA (HR 2·56 [95% CI 1·53–4·28]; p=0·0004). The rates of 1-year sustained minimal residual disease negativity were similar in patients with zero HRCA (53 [35%] of 153] and with one HRCA (57 [41%] of 138) and were lower in patients with two or more HRCA (25 [24%] of 105). The median duration of follow-up from second randomisation was 37 months (IQR 33–42). 3-year progression-free survival from the second randomisation was 80% (95% CI 74–88) in patients with zero HRCA, 68% (95% CI 59–78) in patients with one HRCA, and 53% (95% CI 42–67) in patients with two or more HRCA. The risk of progression or death was higher in patients with one HRCA (HR 1·68 [95% CI 1·01–2·80]; p=0·048) and two or more HRCA (2·74 [95% CI 1·60–4·69], p=0·0003) than in patients with zero HRCA. This preplanned analysis of the FORTE trial showed that carfilzomib-based induction–intensification–consolidation regimens are effective strategies in patients with standard risk (zero HRCA) and high-risk (one HRCA) myeloma, resulting in similar rates of progression-free survival and 1-year sustained minimal residual disease negativity. Despite promising progression-free survival, patients with ultra-high-risk disease (those with 2 or more HRCA) still have an increased risk of progression and death and therefore represent an unmet medical need. Amgen and Celgene/Bristol Myers Squibb. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study.
- Author
-
Waszczuk-Gajda, Anna, Penack, Olaf, Sbianchi, Giulia, Koster, Linda, Blaise, Didier, Reményi, Péter, Russell, Nigel, Ljungman, Per, Trneny, Marek, Mayer, Jiri, Iacobelli, Simona, Kobbe, Guido, Scheid, Christof, Apperley, Jane, Touzeau, Cyrille, Lenhoff, Stig, Jantunen, Esa, Anagnostopoulos, Achilles, Paris, Laura, and Browne, Paul
- Subjects
- *
STEM cell transplantation , *MULTIPLE myeloma , *AUTOGRAFTS , *MONOCLONAL gammopathies , *TREATMENT effectiveness , *BACTERIAL diseases - Abstract
Background: The main goal of this post hoc analysis of the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study was to evaluate the rate of short- and long-term infectious and non-infectious complications occurring after ASCT in patients with multiple myeloma (MM). Methods: The analysis included all patients with MM from the CALM study who underwent ≥1 ASCT. The primary endpoint of the analysis was to determine the rate of infectious and non-infectious complications after ASCT and to compare them in three time periods: 0–100 days, 101 days–1 year, and >1 year after the first transplant. Results: The analysis included a total of 3552 patients followed up for a median of 56.7 months (range 0.4–108.1). Complication rates decreased with the time from ASCT with 24.85 cases per 100 patient-years from day 0 to 100 days after the transplant, and <2.31 cases per 100 patient-years from the 101st day. At 100 days after ASC T, 45.7% of patients had complications, with infectious events being twice as frequent as non-infectious complications. Bacterial infections (6.5 cases per 100 patient-years, 95% CI: 6.1–7.0) and gastrointestinal complications (4.7 cases per 100 patient-years, 95% CI: 4.3–5.1) were the most common early events. The pattern of complications changed with time from ASCT. The presence of complications after ASCT was not associated with overall survival. Conclusions: Our data provide a solid basis for comparing ASCT-related complications to those caused by emerging treatments in multiple myeloma, such as CAR T-cell therapy and other immunotherapies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Safety of outpatient stem cell mobilization with low‐ or intermediate‐dose cyclophosphamide in newly diagnosed multiple myeloma patients.
- Author
-
Pompa, Alessandra, Pettine, Loredana, Giannarelli, Diana, Paris, Laura, Torretta, Lorella, Cavallaro, Francesca, Levati, Giorgia Virginia, Stefanoni, Paola, Mocellin, Cristina, Galli, Monica, and Baldini, Luca
- Subjects
- *
MULTIPLE myeloma , *CYCLOPHOSPHAMIDE , *DIAGNOSIS , *STEM cells , *STEM cell transplantation - Abstract
Objectives: Autologous stem cell transplantation is the gold standard for eligible newly diagnosed multiple myeloma patients. Patients are usually hospitalized for administration of mobilization chemotherapy. We aimed to assess safety and efficacy of mobilization therapy with low‐dose (2 g/m2) and intermediate‐dose (3‐4 g/m2) cyclophosphamide administered as outpatient. Methods: A total of 176 consecutive newly diagnosed transplant‐eligible myeloma patients receiving outpatient mobilization were retrospectively evaluated. Induction therapy was mainly performed with new drugs (91%). Results: Chemotherapy was very well tolerated with 16.6% of patients having all‐grade adverse events (AEs) and only 1.2% having severe AEs. The most frequently reported AEs were nausea and vomiting grade 1‐2 (6.8%). Only 5.7% of patients required hospitalization for AEs. Stem cell collection was successful in 93.1% of patients, with a median CD34+ harvest of 8.7 × 106/kg. Target for 2 autologous stem cell transplantation (at least 6 CD34+ × 106/kg) was reached by 76.3% of patients. Administration of plerixafor on demand was necessary in 12.1% of patients. Conclusions: Outpatient mobilization with low‐ and intermediate‐dose cyclophosphamide appears an efficient and safe procedure, with minimal and manageable AEs and low rate of hospitalization. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use.
- Author
-
Magro, Bianca, Zuccaro, Valentina, Novelli, Luca, Zileri, Lorenzo, Celsa, Ciro, Raimondi, Federico, Gori, Mauro, Cammà, Giulia, Battaglia, Salvatore, Genova, Vincenzo Giuseppe, Paris, Laura, Tacelli, Matteo, Mancarella, Francesco Antonio, Enea, Marco, Attanasio, Massimo, Senni, Michele, Di Marco, Fabiano, Lorini, Luca Ferdinando, Fagiuoli, Stefano, and Bruno, Raffaele
- Subjects
- *
COVID-19 , *HOSPITAL mortality , *RECEIVER operating characteristic curves , *CLINICAL prediction rules , *HEART disease related mortality , *CORONARY disease , *LACTATE dehydrogenase - Abstract
Backgrounds: Validated tools for predicting individual in-hospital mortality of COVID-19 are lacking. We aimed to develop and to validate a simple clinical prediction rule for early identification of in-hospital mortality of patients with COVID-19. Methods and findings: We enrolled 2191 consecutive hospitalized patients with COVID-19 from three Italian dedicated units (derivation cohort: 1810 consecutive patients from Bergamo and Pavia units; validation cohort: 381 consecutive patients from Rome unit). The outcome was in-hospital mortality. Fine and Gray competing risks multivariate model (with discharge as a competing event) was used to develop a prediction rule for in-hospital mortality. Discrimination and calibration were assessed by the area under the receiver operating characteristic curve (AUC) and by Brier score in both the derivation and validation cohorts. Seven variables were independent risk factors for in-hospital mortality: age (Hazard Ratio [HR] 1.08, 95% Confidence Interval [CI] 1.07–1.09), male sex (HR 1.62, 95%CI 1.30–2.00), duration of symptoms before hospital admission <10 days (HR 1.72, 95%CI 1.39–2.12), diabetes (HR 1.21, 95%CI 1.02–1.45), coronary heart disease (HR 1.40 95% CI 1.09–1.80), chronic liver disease (HR 1.78, 95%CI 1.16–2.72), and lactate dehydrogenase levels at admission (HR 1.0003, 95%CI 1.0002–1.0005). The AUC was 0.822 (95%CI 0.722–0.922) in the derivation cohort and 0.820 (95%CI 0.724–0.920) in the validation cohort with good calibration. The prediction rule is freely available as a web-app (COVID-CALC: https://sites.google.com/community.unipa.it/covid-19riskpredictions/c19-rp). Conclusions: A validated simple clinical prediction rule can promptly and accurately assess the risk for in-hospital mortality, improving triage and the management of patients with COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Body Dissatisfaction and Disordered Eating in Three Cultures: Argentina, Brazil, and the U.S.
- Author
-
Forbes, Gordon, Jung, Jaehee, Vaamonde, Juan, Omar, Alicia, Paris, Laura, and Formiga, Nilton
- Subjects
- *
BODY image in women , *EATING disorders in women , *COMPARATIVE sociology , *PSYCHOLOGY , *DISEASE risk factors - Abstract
Body dissatisfaction and associated attitudes were studied in 18-24 years old women from universities in Rosario, Santa Fe, Argentina ( N = 118), João Pessoa, Paraíba, Brazil ( N = 81), and mid-Atlantic U.S. ( N = 102). Based on anecdotal reports, theoretical concerns, and empirical studies, we expected greater body dissatisfaction and negative body attitudes in our Argentine and Brazilian samples than in the U.S. sample. Body dissatisfaction was a significant problem in all samples, but we found few differences in levels of body dissatisfaction. The Argentine and Brazilian samples scored lower than the U.S. sample on measures associated with disordered eating, experienced less pressure to be thin, and were less likely to internalize the thin body ideal. Body shame was highest in the Brazilian sample and lowest in the Argentine sample. Cultural features in Argentina and Brazil that may offer some level of protection against the thin body ideal were discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.